Reckitt Benckiser Group (LON:RKT) Shares Up 1.9% - Time to Buy?

Reckitt Benckiser Group plc (LON:RKT - Get Free Report) rose 1.9% during trading on Monday . The company traded as high as GBX 5,172 ($64.35) and last traded at GBX 5,166 ($64.28). Approximately 90,327,430 shares were traded during mid-day trading, an increase of 757% from the average daily volume of 10,544,096 shares. The stock had previously closed at GBX 5,072 ($63.11).

Wall Street Analyst Weigh In

Separately, Berenberg Bank dropped their price objective on shares of Reckitt Benckiser Group from GBX 5,200 ($64.70) to GBX 5,177 ($64.41) and set a "hold" rating on the stock in a research note on Wednesday, October 23rd.

Reckitt Benckiser Group Stock Up 1.1 %

The company has a current ratio of 0.69, a quick ratio of 0.46 and a debt-to-equity ratio of 112.52. The firm has a 50-day moving average of GBX 4,864.56 and a 200 day moving average of GBX 4,638.58. The stock has a market capitalization of £36.09 billion, a price-to-earnings ratio of 2,406.45, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09.

Insider Buying and Selling

In other Reckitt Benckiser Group news, insider Shannon Eisenhardt sold 1,368 shares of Reckitt Benckiser Group stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of GBX 4,723 ($58.77), for a total value of £64,610.64 ($80,391.49). Insiders own 0.05% of the company's stock.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.